This 2014 prospective case series evaluated the safety and potential efficacy of a metabolic therapy regimen in 10 patients with advanced, chemoresistant metastatic cancers. The treatment combined intravenous alpha-lipoic acid (600 mg), oral hydroxycitrate (500 mg three times daily), and low-dose naltrexone (5 mg at bedtime). Patients included those with
